Sign in

CIK 0001626971

  • Non-accelerated filer
  • Smaller reporting company

Corvus Pharmaceuticals, Inc.

Sign in to watch
Ticker
CRVS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464670809
Phone
+1 650-900-4520
Business address
901 GATEWAY BLVD, THIRD FLOOR, SOUTH SAN FRANCISCO, CA, 94080
  1. 3 Insider Initial Statement of Ownership
  2. 4 Open-market buy President and CEO bought 20,000 shares at $3.29 ($65,884)
  3. 4 Open-market buy Chief Financial Officer bought 24,700 shares at $4.15 ($102,409)
  4. 4 Open-market buy President and CEO bought 10,000 shares at an average $4.40 ($43,950)
  5. 4 Derivatives Options or other derivatives
  6. 4 Gift President and CEO gave 20,000 shares (gift)
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Open-market buy President and CEO bought 5,000 shares at $5.99 ($29,934)
  12. 4 Open-market buy President and CEO bought 1,502 shares at $5.95 ($8,937)
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Derivatives Options or other derivatives
  18. 4 Derivatives Options or other derivatives
  19. 4 Open-market buy Director bought 588,235 shares at $8.50 ($4,999,998)
  20. 4 Open-market buy Director bought 588,235 shares at $8.50 ($4,999,998)

Page 9 of 13 · 252 filings